Ultrahypofractionation of localized prostate cancer : Statement from the DEGRO working group prostate cancer.
Extreme hypofractionation
Hypofractionation
Radiotherapy
SABR
SBRT
Journal
Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]
ISSN: 1439-099X
Titre abrégé: Strahlenther Onkol
Pays: Germany
ID NLM: 8603469
Informations de publication
Date de publication:
Feb 2021
Feb 2021
Historique:
received:
12
11
2020
accepted:
17
11
2020
pubmed:
11
12
2020
medline:
5
5
2021
entrez:
10
12
2020
Statut:
ppublish
Résumé
Due to its low fractionation sensitivity, also known as "alpha/beta ratio," in relation to its surrounding organs at risk, prostate cancer is predestined for hypofractionated radiation schedules assuming an increased therapeutic ratio compared to normofractionated regimens. While moderate hypofractionation (2.2-4 Gy) has been proven to be non-inferior to normal fractionation in several large randomized trials for localized prostate cancer, level I evidence for ultrahypofractionation (>4 Gy) was lacking until recently. An accumulating body of non-randomized evidence has recently been strengthened by the publication of two randomized studies comparing ultrahypofractionation with a normofractionated schedule, i.e., the Scandinavian HYPO-RT trial by Widmark et al. and the first toxicity results of the PACE‑B trial. In this review, we aim to give a brief overview of the current evidence of ultrahypofractionation, make an overall assessment of the level of evidence, and provide recommendations and requirements that should be followed before introducing ultrahypofractionation into routine clinical use.
Identifiants
pubmed: 33301049
doi: 10.1007/s00066-020-01723-8
pii: 10.1007/s00066-020-01723-8
pmc: PMC7726607
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
89-96Références
Morgan SC, Hoffman K, Loblaw DA, Buyyounouski MK, Patton C, Barocas D, Bentzen S, Chang M, Efstathiou J, Greany P, Halvorsen P, Koontz BF, Lawton C, Leyrer CM, Lin D, Ray M, Sandler H (2018) Hypofractionated radiation therapy for localized prostate cancer: executive summary of an ASTRO, ASCO, and AUA evidence-based guideline. Pract Radiat Oncol 8(6):354–360. https://doi.org/10.1016/j.prro.2018.08.002
doi: 10.1016/j.prro.2018.08.002
pubmed: 30322661
Hocht S, Aebersold DM, Albrecht C, Bohmer D, Flentje M, Ganswindt U, Holscher T, Martin T, Sedlmayer F, Wenz F, Zips D, Wiegel T (2017) Hypofractionated radiotherapy for localized prostate cancer. Strahlenther Onkol 193(1):1–12. https://doi.org/10.1007/s00066-016-1041-5
doi: 10.1007/s00066-016-1041-5
pubmed: 27628966
Marzi S, Saracino B, Petrongari MG, Arcangeli S, Gomellini S, Arcangeli G, Benassi M, Landoni V (2009) Modeling of alpha/beta for late rectal toxicity from a randomized phase II study: conventional versus hypofractionated scheme for localized prostate cancer. J Exp Clin Cancer Res 28:117. https://doi.org/10.1186/1756-9966-28-117
doi: 10.1186/1756-9966-28-117
pubmed: 19689825
pmcid: 2733302
Brenner DJ, Hall EJ (1999) Fractionation and protraction for radiotherapy of prostate carcinoma. Int J Radiat Oncol Biol Phys 43(5):1095–1101
doi: 10.1016/S0360-3016(98)00438-6
Fowler J, Chappell R, Ritter M (2001) Is alpha/beta for prostate tumors really low? Int J Radiat Oncol Biol Phys 50(4):1021–1031
doi: 10.1016/S0360-3016(01)01607-8
Dasu A, Toma-Dasu I (2012) Prostate alpha/beta revisited—an analysis of clinical results from 14 168 patients. Acta Oncol 51(8):963–974
doi: 10.3109/0284186X.2012.719635
Proust-Lima C, Taylor JM, Secher S, Sandler H, Kestin L, Pickles T, Bae K, Allison R, Williams S (2011) Confirmation of a low alpha/beta ratio for prostate cancer treated by external beam radiation therapy alone using a post-treatment repeated-measures model for PSA dynamics. Int J Radiat Oncol Biol Phys 79(1):195–201
doi: 10.1016/j.ijrobp.2009.10.008
Miralbell R, Roberts SA, Zubizarreta E, Hendry JH (2012) Dose-fractionation sensitivity of prostate cancer deduced from radiotherapy outcomes of 5,969 patients in seven international institutional datasets: alpha/beta = 1.4 (0.9–2.2) Gy. Int J Radiat Oncol Biol Phys 82(1):e17–e24
doi: 10.1016/j.ijrobp.2010.10.075
Vogelius IR, Bentzen SM (2013) Meta-analysis of the alpha/beta ratio for prostate cancer in the presence of an overall time factor: bad news, good news, or no news? Int J Radiat Oncol Biol Phys 85(1):89–94
doi: 10.1016/j.ijrobp.2012.03.004
Bentzen SM, Lundbeck F, Christensen LL, Overgaard J (1992) Fractionation sensitivity and latency of late radiation injury to the mouse urinary bladder. Radiother Oncol 25(4):301–307
doi: 10.1016/0167-8140(92)90251-O
Dorr W, Bentzen SM (1999) Late functional response of mouse urinary bladder to fractionated X‑irradiation. Int J Radiat Biol 75(10):1307–1315
doi: 10.1080/095530099139476
Tucker SL, Thames HD, Michalski JM, Bosch WR, Mohan R, Winter K, Cox JD, Purdy JA, Dong L (2011) Estimation of alpha/beta for late rectal toxicity based on RTOG 94–06. Int J Radiat Oncol Biol Phys 81(2):600–605. https://doi.org/10.1016/j.ijrobp.2010.11.080
doi: 10.1016/j.ijrobp.2010.11.080
pubmed: 21377288
pmcid: 3163802
Thames HD, Kuban D, Levy LB, Horwitz EM, Kupelian P, Martinez A, Michalski J, Pisansky T, Sandler H, Shipley W, Zelefsky M, Zietman A (2010) The role of overall treatment time in the outcome of radiotherapy of prostate cancer: an analysis of biochemical failure in 4839 men treated between 1987 and 1995. Radiother Oncol 96(1):6–12. https://doi.org/10.1016/j.radonc.2010.03.020
doi: 10.1016/j.radonc.2010.03.020
pubmed: 20400191
Vogelius IR, Bentzen SM (2018) Dose response and fractionation sensitivity of prostate cancer after external beam radiation therapy: a meta-analysis of randomized trials. Int J Radiat Oncol Biol Phys 100(4):858–865. https://doi.org/10.1016/j.ijrobp.2017.12.011
doi: 10.1016/j.ijrobp.2017.12.011
pubmed: 29485063
Baumann M, Holscher T, Denham J (2010) Fractionation in prostate cancer—is it time after all? Radiother Oncol 96(1):1–5. https://doi.org/10.1016/j.radonc.2010.06.001
doi: 10.1016/j.radonc.2010.06.001
pubmed: 20566227
Vogelius IR, Bentzen SM (2020) Diminishing returns from ultrahypofractionated radiation therapy for prostate cancer. Int J Radiat Oncol Biol Phys. https://doi.org/10.1016/j.ijrobp.2020.01.010
doi: 10.1016/j.ijrobp.2020.01.010
pubmed: 32976793
Sher DJ, Parikh RB, Mays-Jackson S, Punglia RS (2014) Cost-effectiveness analysis of SBRT versus IMRT for low-risk prostate cancer. Am J Clin Oncol 37(3):215–221. https://doi.org/10.1097/COC.0b013e31827a7d2a
doi: 10.1097/COC.0b013e31827a7d2a
pubmed: 23275277
Loblaw A (2019) Ultrahypofractionation should be a standard of care option for intermediate-risk prostate cancer. Clin Oncol. https://doi.org/10.1016/j.clon.2019.11.004
doi: 10.1016/j.clon.2019.11.004
Abreha SK (2019) Model-based cost-effectiveness analysis of external beam radiation therapy for the treatment of localized prostate cancer: a systematic review. Cost Eff Resour Alloc 17:10. https://doi.org/10.1186/s12962-019-0178-3
doi: 10.1186/s12962-019-0178-3
pubmed: 31139024
pmcid: 6528358
Lievens Y, Defourny N, Corral J, Gasparotto C, Grau C, Borras JM (2020) How public health services pay for radiotherapy in Europe: an ESTRO-HERO analysis of reimbursement. Lancet Oncol 21(1):e42–e54. https://doi.org/10.1016/s1470-2045(19)30794-6
doi: 10.1016/s1470-2045(19)30794-6
pubmed: 31908306
Mottet N, Bellmunt J, Bolla M, Briers E, Cumberbatch MG, De Santis M, Fossati N, Gross T, Henry AM, Joniau S, Lam TB, Mason MD, Matveev VB, Moldovan PC, van den Bergh RCN, Van den Broeck T, van der Poel HG, van der Kwast TH, Rouviere O, Schoots IG, Wiegel T, Cornford P (2017) EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol 71(4):618–629. https://doi.org/10.1016/j.eururo.2016.08.003
doi: 10.1016/j.eururo.2016.08.003
pubmed: 27568654
Dearnaley D, Syndikus I, Mossop H, Khoo V, Birtle A, Bloomfield D, Graham J, Kirkbride P, Logue J, Malik Z, Money-Kyrle J, O’Sullivan JM, Panades M, Parker C, Patterson H, Scrase C, Staffurth J, Stockdale A, Tremlett J, Bidmead M, Mayles H, Naismith O, South C, Gao A, Cruickshank C, Hassan S, Pugh J, Griffin C, Hall E, CHHiP Investigators (2016) Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5‑year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. Lancet Oncol 17(8):1047–1060. https://doi.org/10.1016/S1470-2045(16)30102-4
doi: 10.1016/S1470-2045(16)30102-4
pubmed: 27339115
pmcid: 4961874
Catton CN, Lukka H, Gu CS, Martin JM, Supiot S, Chung PWM, Bauman GS, Bahary JP, Ahmed S, Cheung P, Tai KH, Wu JS, Parliament MB, Tsakiridis T, Corbett TB, Tang C, Dayes IS, Warde P, Craig TK, Julian JA, Levine MN (2017) Randomized trial of a Hypofractionated radiation regimen for the treatment of localized prostate cancer. J Clin Oncol 35(17):1884–1890. https://doi.org/10.1200/JCO.2016.71.7397
doi: 10.1200/JCO.2016.71.7397
pubmed: 28296582
Lee WR, Dignam JJ, Amin MB, Bruner DW, Low D, Swanson GP, Shah AB, D’Souza DP, Michalski JM, Dayes IS, Seaward SA, Hall WA, Nguyen PL, Pisansky TM, Faria SL, Chen Y, Koontz BF, Paulus R, Sandler HM (2016) Randomized phase III Noninferiority study comparing two radiotherapy fractionation schedules in patients with low-risk prostate cancer. J Clin Oncol 34(20):2325–2339. https://doi.org/10.1200/Jco.2016.67.0448
doi: 10.1200/Jco.2016.67.0448
pubmed: 27044935
pmcid: 4981980
Incrocci L, Wortel RC, Alemayehu WG, Aluwini S, Schimmel E, Krol S, van der Toorn PP, Jager H, Heemsbergen W, Heijmen B, Pos F (2016) Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol 17(8):1061–1069. https://doi.org/10.1016/S1470-2045(16)30070-5
doi: 10.1016/S1470-2045(16)30070-5
pubmed: 27339116
Widmark A, Gunnlaugsson A, Beckman L, Thellenberg-Karlsson C, Hoyer M, Lagerlund M, Kindblom J, Ginman C, Johansson B, Bjornlinger K, Seke M, Agrup M, Fransson P, Tavelin B, Norman D, Zackrisson B, Anderson H, Kjellen E, Franzen L, Nilsson P (2019) Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5‑year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial. Lancet 394(10196):385–395. https://doi.org/10.1016/s0140-6736(19)31131-6
doi: 10.1016/s0140-6736(19)31131-6
pubmed: 31227373
Beck M, Bohmer D, Aebersold DM, Albrecht C, Flentje M, Ganswindt U, Hocht S, Holscher T, Muller AC, Niehoff P, Pinkawa M, Sedlmayer F, Zips D, Zschaeck S, Budach V, Wiegel T, Ghadjar P (2020) Role of combined radiation and androgen deprivation therapy in intermediate-risk prostate cancer : Statement from the DEGRO working group on prostate cancer. Strahlenther Onkol 196(2):109–116. https://doi.org/10.1007/s00066-019-01553-3
doi: 10.1007/s00066-019-01553-3
pubmed: 31784804
Goldner G (2019) Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: HYPO-RT-PC randomized trial. 5‑year results: Commentary II. Strahlenther Onkol 195(12):1119–1121. https://doi.org/10.1007/s00066-019-01536-4
doi: 10.1007/s00066-019-01536-4
pubmed: 31667551
Salembier C, Villeirs G, De Bari B, Hoskin P, Pieters BR, Van Vulpen M, Khoo V, Henry A, Bossi A, De Meerleer G, Fonteyne V (2018) ESTRO ACROP consensus guideline on CT- and MRI-based target volume delineation for primary radiation therapy of localized prostate cancer. Radiother Oncol 127(1):49–61. https://doi.org/10.1016/j.radonc.2018.01.014
doi: 10.1016/j.radonc.2018.01.014
pubmed: 29496279
Brand DH, Tree AC, Ostler P, van der Voet H, Loblaw A, Chu W, Ford D, Tolan S, Jain S, Martin A, Staffurth J, Camilleri P, Kancherla K, Frew J, Chan A, Dayes IS, Henderson D, Brown S, Cruickshank C, Burnett S, Duffton A, Griffin C, Hinder V, Morrison K, Naismith O, Hall E, van As N (2019) Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial. Lancet Oncol 20(11):1531–1543. https://doi.org/10.1016/s1470-2045(19)30569-8
doi: 10.1016/s1470-2045(19)30569-8
pubmed: 31540791
pmcid: 6838670
King CR, Freeman D, Kaplan I, Fuller D, Bolzicco G, Collins S, Meier R, Wang J, Kupelian P, Steinberg M, Katz A (2013) Stereotactic body radiotherapy for localized prostate cancer: pooled analysis from a multi-institutional consortium of prospective phase II trials. Radiother Oncol 109(2):217–221. https://doi.org/10.1016/j.radonc.2013.08.030
doi: 10.1016/j.radonc.2013.08.030
pubmed: 24060175
Kishan AU, Dang A, Katz AJ, Mantz CA, Collins SP, Aghdam N, Chu FI, Kaplan ID, Appelbaum L, Fuller DB, Meier RM, Loblaw DA, Cheung P, Pham HT, Shaverdian N, Jiang N, Yuan Y, Bagshaw H, Prionas N, Buyyounouski MK, Spratt DE, Linson PW, Hong RL, Nickols NG, Steinberg ML, Kupelian PA, King CR (2019) Long-term Outcomes of Stereotactic Body Radiotherapy for Low-Risk and Intermediate-Risk Prostate Cancer. JAMA Netw Open 2(2):e188006. https://doi.org/10.1001/jamanetworkopen.2018.8006
doi: 10.1001/jamanetworkopen.2018.8006
pubmed: 30735235
pmcid: 6484596
Jackson WC, Silva J, Hartman HE, Dess RT, Kishan AU, Beeler WH, Gharzai LA, Jaworski EM, Mehra R, Hearn JWD, Morgan TM, Salami SS, Cooperberg MR, Mahal BA, Soni PD, Kaffenberger S, Nguyen PL, Desai N, Feng FY, Zumsteg ZS, Spratt DE (2019) Stereotactic body radiation therapy for localized prostate cancer: a systematic review and meta-analysis of over 6,000 patients treated on prospective studies. Int J Radiat Oncol Biol Phys 104(4):778–789. https://doi.org/10.1016/j.ijrobp.2019.03.051
doi: 10.1016/j.ijrobp.2019.03.051
pubmed: 30959121
pmcid: 6770993
Roach M 3rd, Hanks G, Thames H Jr., Schellhammer P, Shipley WU, Sokol GH, Sandler H (2006) Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 65(4):965–974. https://doi.org/10.1016/j.ijrobp.2006.04.029
doi: 10.1016/j.ijrobp.2006.04.029
pubmed: 16798415
pmcid: 16798415
Boeve LMS, Hulshof M, Vis AN, Zwinderman AH, Twisk JWR, Witjes WPJ, Delaere KPJ, Moorselaar R, Verhagen P, van Andel G (2019) Effect on survival of androgen deprivation therapy alone compared to androgen deprivation therapy combined with concurrent radiation therapy to the prostate in patients with primary Bone metastatic prostate cancer in a prospective Randomised clinical trial: data from the HORRAD trial. Eur Urol 75(3):410–418. https://doi.org/10.1016/j.eururo.2018.09.008
doi: 10.1016/j.eururo.2018.09.008
pubmed: 30266309
Parker CC, James ND, Brawley CD, Clarke NW, Hoyle AP, Ali A, Ritchie AWS, Attard G, Chowdhury S, Cross W, Dearnaley DP, Gillessen S, Gilson C, Jones RJ, Langley RE, Malik ZI, Mason MD, Matheson D, Millman R, Russell JM, Thalmann GN, Amos CL, Alonzi R, Bahl A, Birtle A, Din O, Douis H, Eswar C, Gale J, Gannon MR, Jonnada S, Khaksar S, Lester JF, O’Sullivan JM, Parikh OA, Pedley ID, Pudney DM, Sheehan DJ, Srihari NN, Tran ATH, Parmar MKB, Sydes MR (2018) Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. Lancet 392(10162):2353–2366. https://doi.org/10.1016/s0140-6736(18)32486-3
doi: 10.1016/s0140-6736(18)32486-3
pubmed: 30355464
pmcid: 6269599
Nason GJ, Hamilton RJ (2019) Treating the primary in metastatic prostate cancer: where do we stand? Curr Opin Support Palliat Care 13(3):243–248. https://doi.org/10.1097/spc.0000000000000432
doi: 10.1097/spc.0000000000000432
pubmed: 31082943
Fowler JF, Toma-Dasu I, Dasu A (2013) Is the alpha/beta ratio for prostate tumours really low and does it vary with the level of risk at diagnosis? Anticancer Res 33(3):1009–1011
pubmed: 23482774
Kishan AU, Tyran M, Weng J, Upadhyaya S, Lamb J, Steinberg M, King C, Cao M (2019) Stereotactic body radiotherapy to the prostate and pelvic lymph nodes: A detailed dosimetric analysis of a phase II prospective trial. Br J Radiol 92(1099):20181001. https://doi.org/10.1259/bjr.20181001
doi: 10.1259/bjr.20181001
pubmed: 30912957
pmcid: 6636273
Murthy V, Mallick I, Gavarraju A, Sinha S, Krishnatry R, Telkhade T, Moses A, Kannan S, Prakash G, Pal M, Menon S, Popat P, Rangarajan V, Agarwal A, Kulkarni S, Bakshi G (2020) Study protocol of a randomised controlled trial of prostate radiotherapy in high-risk and node-positive disease comparing moderate and extreme hypofractionation (PRIME TRIAL). BMJ Open 10(2):e34623. https://doi.org/10.1136/bmjopen-2019-034623
doi: 10.1136/bmjopen-2019-034623
pubmed: 32114475
pmcid: 7050316